Hamilton Lane Inc Stock Price, News & Analysis

Grenova, a Virginia-based sustainable laboratory technologies company, has announced two major developments: the appointment of Ted Hull to its board and the completion of a new growth equity capital round. Hull brings over 30 years of life sciences experience, including 20+ years as a clinical lab CEO.

The new funding, led by Peloton Equity and Hamilton Lane's (Nasdaq: HLNE) Impact Fund II, along with other existing investors, will be utilized to enhance Grenova's automation portfolio, expand R&D capabilities, and grow the team to meet global market demand. The company focuses on transforming single-use laboratory plastics into sustainable, reusable solutions.

PAX Health, backed by HCAP Partners and Hamilton Lane (Nasdaq:HLNE), has announced the acquisition of Richardson Psychiatric Associates, a comprehensive outpatient psychiatric practice in Western Pennsylvania. The strategic move expands PAX Health's mental health service portfolio and geographical presence.

Founded by Dr. W. Randolph Richardson and Lisa Richardson, PMHNP-BC, the acquired practice specializes in psychiatric evaluations, medication management, and various therapeutic approaches including Cognitive Behavioral Therapy, Trauma Therapy, Art Therapy, and Grief Therapy. Dr. Richardson has practiced since 1991, while Lisa has worked in psychiatry since 1987.

The integration aims to enhance PAX Health's ability to deliver customized behavioral health solutions while maintaining Richardson Psychiatric Associates' established patient care approach. The acquisition represents a significant step in PAX Health's growth strategy, focusing on improving access to comprehensive behavioral healthcare services.

Hamilton Lane (HLNE) has announced an investment in a $74 million NYC multifamily portfolio, acquiring an 85% interest in four Manhattan properties from a family office seller. The portfolio includes 126 multifamily units and 11,050 square feet of retail space in West Village and SoHo neighborhoods.

The transaction is structured as a partnership with Dalan Real Estate, which retains a 15% stake and will continue operating the buildings. The investment comes amid a 20% decline in U.S. real estate values over the past two years, which Hamilton Lane views as an opportunistic timing for acquiring prime location assets.

Hamilton Lane's Real Estate platform, with nearly $109 billion in assets under management and supervision as of December 31, 2024, has been actively investing in real estate for over 25 years.

Hamilton Lane (HLNE) has launched the first U.S. private infrastructure fund available to retail investors through Republic's platform. The Hamilton Lane Private Infrastructure Fund (HLPIF) allows non-accredited investors to access infrastructure investments with a minimum of $500, marking a significant democratization of private markets.

The fund focuses on capital-intensive fixed assets with high barriers to entry and pre-contracted cash flows spanning 10-15 years. Investment targets include hyperscale data centers, international airports, and natural gas pipelines. The infrastructure sector has grown from $500 million in 1999 to $1.2 trillion in assets under management today.

HLPIF is structured as a continuously offered closed-end management investment company under the '40 Act. The fund plans to conduct quarterly repurchase offers of up to 5% of net assets and intends to offer additional liquidity through tokenization following regulatory review.

Hamilton Lane (HLNE) has released its 2025 Market Overview, providing a comprehensive analysis of private markets based on data from over 58,000 funds across 57 vintage years. The report highlights both opportunities and challenges in the private markets landscape.

Key investment recommendations include focusing on credit, infrastructure, and secondaries, maintaining exposure to venture and growth sectors (particularly AI), and targeting U.S. markets over other geographies for the next 4-5 years. The report emphasizes strong opportunities in co-investments and equity sectors where selective positioning is possible.

While short-term performance shows infrastructure and real estate performing well and private credit remaining stable, private equity has experienced recent underperformance. However, long-term fundamentals remain robust, with private credit outperforming public markets for 23 consecutive years and infrastructure maintaining outperformance for 12 years.

The report predicts significant growth in evergreen structures, projecting faster growth than public markets over the next five years, with institutional investors increasing their presence and fees likely to decline.

Hamilton Lane (Nasdaq: HLNE) has launched the Hamilton Lane Private Secondary Fund (HLPSF), a new evergreen investment vehicle registered under the Investment Company Act of 1940. The fund targets U.S. accredited investors and qualified high-net-worth individuals, offering access to the firm's secondary investment platform.

Key features include:

• Quarterly liquidity potential
• Low investment minimums of $25K
• Immediate access to mature private equity investments
• Focus on partially to fully funded secondary investments

The fund aims to provide favorable risk-adjusted returns through a diversified portfolio across sponsors, strategies, industries, vintages, and geographies. It is part of Hamilton Lane's broader secondaries platform, which manages $24.1 billion in assets as of December 31, 2024, and extends the firm's $9+ billion Evergreen Platform.

Cosette Pharmaceuticals has announced a definitive agreement to acquire Mayne Pharma Group for approximately USD $430 Million at AUD$7.40 per share. The transaction is expected to close in Q2 2025.

The acquisition will transform Cosette into a leading player in women's health and dermatology in the U.S., combining Cosette's 350+ strong team with Mayne Pharma's 480+ workforce. The merged entity will operate two FDA-approved manufacturing facilities in Lincolnton, North Carolina and Salisbury, South Australia.

Post-acquisition, Cosette will market 12 patent-protected products including notable brands such as VYLEESI®, INTRAROSA®, NEXTSTELLIS®, ANNOVERA®, BIJUVA®, IMVEXXY® and RHOFADE®. The transaction has received approval from both companies' Boards of Directors, with Mayne Pharma's Board unanimously recommending shareholders vote in favor.

73 Strings has secured a $55 million Series B funding round led by Growth Equity at Goldman Sachs Alternatives, with participation from Blackstone Innovations Investments, Golub Capital, Hamilton Lane (HLNE), and Broadhaven Ventures. The company, which provides AI-powered data extraction, monitoring, and valuation solutions for the $17.6 Trillion AUM Alternative Asset Management space, will use the funds to accelerate product development and innovation.

The platform serves clients managing nearly $10 trillion in assets, enabling faster and more frequent valuations with enhanced transparency. The company plans to expand its capabilities through: building smarter systems with LLMs, implementing benchmarking & predictive analytics, introducing portfolio simulation features, and launching advanced dashboards specifically designed for private capital data.

PSG, a growth equity firm focused on software and technology-enabled services, has announced the closure of two funds totaling $8 billion in capital commitments. The firm's sixth North American flagship fund, PSG VI, closed at $6 billion, exceeding its predecessor fund of $4.7 billion. Additionally, PSG closed a $2 billion continuation fund, PSG Sequel, backed by major institutional investors including CPP Investments, GIC, StepStone, and Hamilton Lane.

PSG Sequel will maintain stakes in six portfolio companies: Arcoro, LivTech, Nextlane, Semarchy, Singlewire Software, and Transit Technologies. The firm, founded in 2014, has grown to manage over $28 billion in assets, with 269 professionals including 160 investment professionals. PSG has executed 75 realization events and expanded globally with offices in Boston, London, Kansas City, Paris, Madrid, and Tel Aviv. The firm has invested in 19 AI-driven companies and continues to leverage AI across its portfolio.